Why Galderma Group (SWX:GALD) Is Back In The Spotlight

Fresh three year Nemluvio data from the ARCADIA and OLYMPIA extension studies has pushed Galderma Group (SWX:GALD) back into focus for investors watching dermatology focused drug platforms.

Nemluvio’s three year readout lands as Galderma Group’s share price has edged higher, with a 7 day share price return of 2.74% and a 30 day share price return of 6.45%, although the 90 day share price return declined 3.34%. The year to date share price return of 3.03%, alongside a 1 year total shareholder return of 15.68%, points to momentum that has recently firmed again, helped by a steady run of product announcements and fresh clinical data.

Capitalize on the renewed focus on Galderma Group’s dermatology platform by scanning a handpicked set of peers with resilient balance sheets using our list of solid balance sheet and fundamentals (204 results).

Galderma Group now trades at a double discount, around 19% below the average analyst price target and roughly 47% below one intrinsic value estimate. After the recent rebound, is that caution still warranted or is it already stretched?

Most Popular Narrative: 17% Undervalued

Against the last close of CHF164.95, the most followed narrative pegs Galderma Group’s fair value at CHF197.55, framing the current discount through the lens of Nemluvio and the broader dermatology franchise.

The strong uptake and market share gains of newly launched products like Nemluvio and Relfydess, driven by their differentiated clinical profiles and positive physician reception, are likely to accelerate Galderma's top-line growth and expand the addressable market, especially as global population aging and heightened focus on appearance drive continued demand for dermatological and aesthetic treatments, positively impacting future revenues.

See why 13 investors see Galderma Group as 17% undervalued.

Result: Fair Value of CHF197.55 (UNDERVALUED)

Still, the Galderma Group narrative leans heavily on Nemluvio and injectable aesthetics, so any pricing pressure or regulatory setbacks could quickly challenge that under valuation story.

Find out about the key risks to this Galderma Group narrative.

Another Look At Galderma Group’s Valuation

The earlier view presents Galderma Group as undervalued based on intrinsic value analysis, yet the straightforward P/E perspective points in a different direction. At roughly 53.7x earnings, the shares trade well above the European pharmaceuticals average on 18.8x and peers on 33.9x, while the fair ratio is lower again at 43.4x. Is the discount to fair value a cushion, or is the high multiple a signal that expectations are already elevated?

See what the numbers indicate about this price in more detail with our valuation breakdown, starting with See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Sentiment around Galderma Group has leaned optimistic, yet the real edge comes from reviewing the underlying data yourself and deciding fast where you stand. To see what investors view as the most important upside drivers, start with the 3 key rewards.

Looking for more investment ideas beyond Galderma Group?

If you like the Galderma Group story but do not want all your capital tied to a single healthcare stock, broaden your watchlist using focused screeners that surface specific qualities across the market.

• Target resilient compounding potential by scanning a curated universe of companies that appear mispriced on quality and fundamentals through our 177 high quality undervalued stocks.
• Strengthen your income stream by zeroing in on businesses with robust payouts and higher yields using the 223 dividend fortresses.
• Dial down portfolio stress by focusing on companies with stronger finances and lower perceived risk through the 223 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com